Paul Diaz: Yes. I mean, it’s probably the biggest opportunity for precision medicine as we see it. And as Dale presented at JPMorgan, we really do think that we’ll have a very competitive product. Our analytical validation work has gone well. We’ll be announcing shortly the clinical work that we’re doing with a couple of academic medical centers on the clinical validation. But we have a lot of interest on the research side already, and that coincides with our other biopharma work on companion diagnostics as I mentioned before. So we’re looking for 2023 to start that research, contribute more meaningfully in 2024, and then a commercial launch in 2025. I think that’s a realistic timeframe. And I do think some of the great work some of our competitors have done have paved the way quite frankly for us to be able to get reimbursement.
And that’s a great expertise of the company. Our proudness may be overstating a little bit. But one of our strength is clearly reimbursement, regulatory and working through FDA and other channel. So it’s a big market. We think there’ll be room for many of us. And quite frankly, I’m really focused with some of our big customers on not only the clinical piece, but how does it get integrated into practice? And how do we make a good case for payers that in the course of treatment they should pay for it. I think this industry has struggled with not answering those last two questions, and those are front and center of our product management deliberations. We’ve got to have a really good product, but it has to be something that fits into the clinic, into the course of treatment and payers need to be able to see the value proposition as well in terms of their total cost of care.
Unidentified Analyst: Got it. Thank you.
Operator: And your next question will come from the line of Jack Meehan with Nephron Research. Your line is open.
Jack Meehan: Thank you. Good afternoon. I had a two part question on GeneSight. So first, Can you talk about the sequential trends in the quarter? Look like volume and revenue were down a touch, haven’t seen that move in volume in a while. So just was there anything notable there? And then second, Paul, you talked about 20% plus growth kind of long-term. Is that inclusive of 2023?
Paul Diaz: Yes. I mean, there are quarterly variations for different reasons. And so, I — look, we have to report out things quarterly, but we don’t run company that way and the healthcare system doesn’t really work that way, Jack. So we are plus 20 start for the year through January and February on volume. Deductibles affect things in the first quarter. There’s a lot of moving parts in the first quarter. A lot of volume that we got to push through the labs. So our folks are working overtime and weekends to make sure that the demand is actually gets by the end of the quarter reported. So there’s a lot of work happening. And keep in mind that this is all happening while we’re trying to stand up our labs of the future and all of that and keep turnaround times at an industry 5.5 days.
But there is nothing with GeneSight other than upward momentum. And we’re making great progress on the coverage front as well and we’ll probably be able to talk about that over the next couple of quarters.
